SCHEMBL24853451

SCHEMBL24853451

COc1ccc(CNC2(CCc3ccc(C)nc3Cl)CCN(Cc3ccccc3)C2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
POLB P06746 2/20 0.42
SIGMAR1 Q99720 3/20 0.42
KDM4E B2RXH2 1/20 0.40
ACHE P22303 1/20 0.40
BACE1 P56817 1/20 0.40
CLPP Q16740 1/20 0.39
MMP1 P03956 1/20 0.39
MMP9 P14780 1/20 0.39
MMP13 P45452 1/20 0.39
ADAM17 P78536 1/20 0.39
NR3C1 P04150 1/20 0.39
CYP2D6 P10635 3/20 0.38
TSHR P16473 2/20 0.38
CYP3A4 P08684 2/20 0.38
ALDH1A1 P00352 2/20 0.38
HTR1A P08908 1/20 0.38
HTR1D P28221 1/20 0.38
HTR1B P28222 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30318752 1.00 MEN1 (0.42) MEN1KMT2APOLBSIGMAR1KDM4E
SCHEMBL24853455 0.77 SIGMAR1 (0.42) MEN1KMT2APOLBSIGMAR1KDM4E
SCHEMBL30318699 0.77 SIGMAR1 (0.42) MEN1KMT2APOLBSIGMAR1KDM4E
SCHEMBL31207277 0.74 TP53 (0.33) POLBKDM4ECYP3A4ALDH1A1CYP1A2
SCHEMBL31099097 0.74 LMNA (0.40) BACE1MMP13ADAM17ALDH1A1
SCHEMBL31207273 0.74 LMNA (0.40) BACE1MMP13ADAM17ALDH1A1
SCHEMBL24853447 0.71 SIGMAR1 (0.53) MEN1KMT2APOLBSIGMAR1KDM4E
SCHEMBL31099096 0.70 LMNA (0.34) MEN1KMT2AKDM4EBACE1ALDH1A1
SCHEMBL31207239 0.70 LMNA (0.34) MEN1KMT2AKDM4EBACE1ALDH1A1
SCHEMBL31207250 0.70 LMNA (0.34) MEN1KMT2AKDM4EBACE1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250084084-A1 Crystalline form of (2R)-2-(5-fluoro-2-methoxypyridin-4-yl)-1-[(2S)-7-methyl-6-(pyrimidin-2-yl)-3,4-dihydro-1H-spiro[1,8-naphthyridine-2,3-pyrrolidin]-1-yl]propan-1-one PFIZER INC. (US) 2025-03-13 US disclosed
EP-4161927-B9 SPIRO COMPOUNDS AS MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF PFIZER (US) 2024-11-06 EP disclosed
EP-4161927-B1 SPIRO COMPOUNDS AS MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF PFIZER (US) 2024-08-07 EP disclosed
US-20230174532-A1 METHODS FOR ANTAGONIZING A MELANOCORTIN 4 RECEPTOR PFIZER INC. (US) 2023-06-08 US disclosed
US-20230174532-A1 METHODS FOR ANTAGONIZING A MELANOCORTIN 4 RECEPTOR PFIZER INC. (US) 2023-06-08 US disclosed
US-20230174532-A1 METHODS FOR ANTAGONIZING A MELANOCORTIN 4 RECEPTOR PFIZER INC. (US) 2023-06-08 US disclosed
CN-116113635-A Spiro compounds as melanocortin 4 receptor antagonists and uses thereof 辉瑞公司 2023-05-12 CN disclosed
US-11643412-B2 Melanocortin 4 receptor antagonists and uses thereof PFIZER INC. (US) 2023-05-09 US disclosed
US-11643412-B2 Melanocortin 4 receptor antagonists and uses thereof PFIZER INC. (US) 2023-05-09 US disclosed
US-11643412-B2 Melanocortin 4 receptor antagonists and uses thereof PFIZER INC. (US) 2023-05-09 US disclosed
EP-4161927-A1 SPIRO COMPOUNDS AS MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF Pfizer Inc. (US) 2023-04-12 EP disclosed
US-20230019853-A1 MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF PFIZER INC. (US) 2023-01-19 US disclosed
US-20230019853-A1 MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF PFIZER INC. (US) 2023-01-19 US disclosed
WO-2023275715-A1 METABOLITES OF SELECTIVE ANDROGEN RECEPTOR MODULATORS PFIZER INC. (US) 2023-01-05 WO disclosed
WO-2023275715-A1 METABOLITES OF SELECTIVE ANDROGEN RECEPTOR MODULATORS PFIZER INC. (US) 2023-01-05 WO disclosed
WO-2021250541-A1 SPIRO COMPOUNDS AS MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF PFIZER INC. (US) 2021-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250084084-A1 Crystalline form of (2R)-2-(5-fluoro-2-methoxypyridin-4-yl)-1-[(2S)-7-methyl-6-(pyrimidin-2-yl)-3,4-dihydro-1H-spiro[1,8-naphthyridine-2,3-pyrrolidin]-1-yl]propan-1-one CSPP1, PRNP, RPLP2 MEN1 1380/4885KMT2A 1048/4885POLB 2060/4885
US-20230019853-A1 MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF MC4R, MC3R, MC5R MEN1 182/4885KMT2A 1777/4885POLB 4623/4885
US-20230174532-A1 METHODS FOR ANTAGONIZING A MELANOCORTIN 4 RECEPTOR MC4R, MC2R, NPY4R MEN1 527/4885KMT2A 2106/4885POLB 4679/4885
US-11643412-B2 Melanocortin 4 receptor antagonists and uses thereof MC4R, MC3R, MC5R MEN1 182/4885KMT2A 1777/4885POLB 4623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.